ThermoGenesis has promoted president and COO William Osgood to the CEO post. He replaces company founder Phil Coelho, who takes over as chief technology architect.
NovaDel Pharma announced Jan H. Egberts, M.D., has resigned as president and CEO and as a member of the board of directors. The NovaDel board has appointed Steven B. Ratoff, chairman of the board, to serve as interim president and CEO.
Merck has appointed Kenneth C. Frazier president of the global human health unit. Bruce N. Kuhlik will replace Frazier as general counsel.
Troubled Point Therapeutics has axed much of its executive staff. The biotech terminated the employment of Donald Kiepert, chairman and CEO; Richard Small, senior vice president and CFO; Michael Duffy, senior vice president and general counsel; and Barry Jones, PhD., senior vice president and CSO.
Nicholas Franco has joined Axcan Pharma as senior vice president, international commercial operations.
Med BioGene announced that Dr. Nathan Yoganathan, MBI's founder, president and CSO, has transitioned to a senior advisory role as chief scientific advisor. Dr. Bradley McLean, a senior scientist with MBI, was appointed chief scientific officer.
Ardea Biosciences has appointed Patrick M. O'Connor, PhD, senior vice president, research and preclinical development and chief scientific officer.
Aspreva is replacing its chief scientific officer, Dr. Richard Jones, as part of a restructuring plan. He will be replaced by Dr. Usman Azam, the company's chief medical officer.
BioCryst has hired Stuart Grant, who had been with Serono, as its new CFO.
Metabolix announced that Thomas Auchincloss has resigned as CFO, treasurer and vice president of finance and corporate development.
Phytomedics has enlisted industry veteran Arthur H. Finnel to be its chief financial officer.
Peregrine Pharmaceuticals has named Mary J. Boyd, Ph.D. as head of business development for Asia and Europe.
OXiGENE has named Patricia Walicke, M.D., Ph.D., as chief medical officer and vice president.
Affymax has appointed Anne-Marie Duliege as chief medical officer. Duliege will lead the clinical, medical and regulatory affairs departments and will have responsibility for clinical development of its pipeline of products.
ImmunoGen announced that Pauline Jen Ryan, senior vice president of corporate development and operations, is leaving the company to pursue other interests.
MAP Pharmaceuticals has named Charlene A. Friedman as vice president, general counsel and secretary.
EyeGate Pharma has named Michael A. Patane, Ph.D., as vice president of research and development and promoted Michael P. Manzo to vice president of engineering.
Kendle has named Thomas B. Smith, MD, as vice president, medical affairs.
EKR Therapeutics has named Tong Zhang, Ph.D. to the newly created position of director of business development.
Reflect Scientific has retained the services of Juan A. Benitez as a consultant.
Elusys Therapeutics has appointed Ron Eastman as chairman of the board of directors, succeeding William R. Miller.
XOMA has elected Charles J. Fisher, M.D. to its board of directors.
AVAX Technologies has named Dr. Francois Martelet as a director.
GeneNews Limited has named Dr. Bernard Levin to chair its newly formed Colorectal Cancer Clinical Advisory Board.